Tevogen expands T cell therapy pipeline across viral and cancer indications

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) reported advancements in its cell therapy platform and pipeline expansion across multiple disease areas during 2025, according to a company statement issued from the J.P. Morgan Healthcare Conference.

The Warren, New Jersey-based biotechnology company said it enhanced its proprietary ExacTcell platform to increase laboratory yields of target-specific cytotoxic T lymphocytes per product, aimed at improving consistency and throughput for clinical supply and manufacturing.

Tevogen completed T cell target identification for five additional HLA restrictions, expanding potential patient coverage for its SARS-CoV-2-specific CTL product. The company advanced target discovery and preclinical activities for CTL therapies addressing Epstein-Barr virus associated lymphomas, chronic hepatitis B, and human papilloma virus related cancers.

The company's Tevogen.AI division supported peptide target identification and prioritization across CTL programs. Tevogen also advanced its strategy to establish in-house GMP cell therapy manufacturing capabilities.

"2025 was a defining execution year for Tevogen," said Ryan Saadi, founder and CEO. "We have built a scalable CTL platform, expanded into multiple high-value indications, and laid the manufacturing foundation required to translate our science into clinical and commercial outcomes."

Tevogen previously completed a proof-of-concept clinical trial for its single-HLA-restricted, genetically unmodified allogeneic T cells. The company's pipeline spans virology, oncology, and neurology programs built on the ExacTcell platform.

You May Also Be Interested In

• Winnebago Industries refinances credit facility, extends maturity to 2031
• Cytek faces $56M damages award in Beckman Coulter patent case
• Nuvectis Pharma (NVCT) files $200M mixed shelf